Krill oil has been well-researched for heart disease, high levels of triglycerides, high cholesterol, high blood pressure, osteoarthritis, and many other pressing health conditions. While krill oil contains fatty acids similar to those found in fish oil, both ingredients are poorly absorbed in the body after consumed, which leads to larger capsules and higher serving counts to achieve optimal therapeutic blood levels. In addition, EFAs are also known to be heavily food dependent for optimal oral absorption and bioavailability.
To overcome these obstacles, SourceOne leverages the VESIsorb® delivery system, therefore achieving industry benchmarks for unprecedented active loading, improved bioavailability, and mitigating food dependency. Human clinical trials have demonstrated the dramatic improvement in pharmacokinetic performance (Cmax, Tmax, and AUC) of omega-3 EFA VESIsorb® formulations, showing up to a 26-fold improvement compared to a leading Rx brand.
The benefits are unmatched:
- Faster onset, independent of food/fat status.
- Fewer servings required to achieved the desired therapeutic effect.
- Superior loading for smaller and easier to consumer capsules.
- Addressing issues related to poor absorption like age, diet, and gender.
Simply put, this formula delivers unmatched blood plasma levels of both omega-3 fish oil EFAs and Superba™ krill oil in an elegant softgel capsule.
While consumer compliance is a major concern for medical professionals recommending omega-3 solution, fewer servings are required of MEGA KRILL™ (compared to other natural solutions) to achieve the desired therapeutic effect which dramatically improves this concern.
* Superba™ krill oil is a trademark of AKER BIOMARINE ANTARTIC.